Penny chatter
2月前
Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment
Source: GlobeNewswire Inc.?
Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received a new patent approval from the United States Patent and Trademark Office, marking another significant advancement in its proprietary MEAI-based binge behavior regulator program.
The approved patent claims cover, among other things, a method of regulating the consumption of alcoholic beverages and a method of controlling binge behavior through the administration of an amine aminoindane, including 5-methoxy-2-aminoindan (MEAI), the Company's innovative psychedelic molecule. This latest patent further bolsters Clearmind’s extensive intellectual property portfolio in the psychedelic sector, which now includes 29 granted patents across 19 patent families, with protections secured in key jurisdictions such as the U.S., Europe, China, and India.
Dr. Adi Zuloff-Shani, CEO of Clearmind, commented, “We are proud to continue leading the way in IP protection within this space. Expanding and maintaining our patent portfolio, particularly in the U.S., remains a key objective for us. We believe that we hold one of the largest portfolios in the market, covering our core areas: MEAI, binge behavior, addictions, mental disorders, as well as new psychedelic compounds and combinations identified and researched by our team.”
MEAI is a novel psychoactive molecule that reduces the desire to consume alcoholic beverages while providing a mild euphoric, alcohol-like experience. It holds the potential to transform the lives of millions who struggle with moderating their alcohol intake. Clearmind’s MEAI-based flagship treatment targets Alcohol Use Disorder (AUD) and weight loss. AUD is a widespread condition that ranges from mild to severe and is characterized by an individual’s inability to control their alcohol consumption despite adverse social, occupational, or health consequences. Clearmind’s MEAI may also be effective in treating binge drinking, a potentially life-threatening addiction.
subslover
3月前
Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders
Vancouver, Canada, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the submission of a patent application under the international Patent Cooperation Treaty (“PCT”) as part of the company’s ongoing collaboration with the with Yissum Research Development Company of the Hebrew University of Jerusalem (“Yissum”) pursuant to the exclusive licensing agreement that the Company entered into with Yissum.
This patent application refers to generation 3.0 of psychedelic compounds, methods of their preparation and uses thereof in the treatment of mental disorders and was developed by Prof. Dmitry Tsvelikhovsky of the Hebrew University of Jerusalem.
The PCT submission will allow the company to proceed to the national phase, which involves submitting applications to regional offices in various countries to seek patent protection in major jurisdictions like the US, Europe, China and India.
Dr. Adi Zuloff-Shani, CEO of Clearmind, commented, "Under the exclusive global license agreement we signed with Yissum, this patent submission, if approved, will secure the intellectual property rights of this important patent for the company. We strongly believe in the potential of psychedelic treatments to become a vital tool in treating, mental disorders and we see Clearmind, as a leading company in the space, continuing to drive innovation. We believe that this next generation psychedelic, featuring new and advanced molecules may offer an excellent therapeutic option to improve quality of life for patients suffering from mental disorders.”
TheFinalCD
12月前
Clearmind Medicine Closes US$2.25 Million Public Offering
https://finance.yahoo.com/news/clearmind-medicine-closes-us-2-161600535.html
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173179438
Message in reply to:
$CMND .14 couple reasons why I like it:
7.5m share Offering @ .30 closed, we are trading less than 50% of offering price
They submitted an IND to the FDA on March 16, 2023 they are overdue to hear back from FDA, any positive news and this goes
On 10/26 there was a SC13G filed for 7.7% or 1.2m shares
At or near bottom, low risk imo, watching for breakout over .15 with sustained vol.